Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II TrialChunyan Lan, Xin Huang, JingXian Shen et al.|Journal of Clinical Oncology|2020Cited by 217
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal CarcinomaYe‐Lin Liang, Jing‐Ping Yun, Xu Liu et al.|JAMA|2025Cited by 67
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal CarcinomaYusheng Jie, Cheng Xu, Xiaoyu Liang et al.|JAMA|2025Cited by 26
PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).Jun Ma, Yu‐Pei Chen, Ying Sun et al.|Journal of Clinical Oncology|2023Cited by 19
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.Jun Ma, Jibin Li, Ying Sun et al.|Journal of Clinical Oncology|2024Cited by 17